Astellas Pharma Inc (ALPMY) 15.4200 $ALPMY Sanofi's Bid

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMY) 15.4200 $ALPMY

Sanofi's Bid for Medivation Is Too Low
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 1:38PM CDT
Image source: Flickr user StockMonkeys.com. After waiting for weeks for a reply to its M&A offer, drug giant Sanofi has gone public with a $9.3 billion bid to acquire mid-cap cancer drugmaker Medivation  . Sanofi's purchase price is...
MDVN: 58.89 (-0.08), JNJ: 116.46 (+0.28), GILD: 82.45 (+0.66), SNY: 40.29 (+0.50), NVS: 79.71 (+0.25)

J&J's Q1 Results Suggest More Upside for Medivation, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 27, 7:01AM CDT
SOURCE: JOHNSON & JOHNSON Johnson & Johnson has reported its first-quarter financials, and the report shows that market share for its top selling prostate cancer drug Zytiga slipped slightly in the quarter. The loss of market share in...
MDVN: 58.89 (-0.08), JNJ: 116.46 (+0.28)

Medivation/Astellas' Xtandi Gets CHMP Nod to Include Data
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 10:50AM CDT
Medivation (MDVN) and Astellas (ALPMY) announced that the EMA's CHMP has issued a positive opinion in favor of the inclusion of new data in Xtandi's label.
MDVN: 58.89 (-0.08), AZN: 28.70 (+0.06), AMAG: 24.46 (+0.83)

Medivation Prostate Cancer Drug Xtandi under Pricing Attack
Arpita Dutt - Zacks Investment Research - Tue Mar 29, 9:30AM CDT
Americans are charged more for Medivation's (MDVN) prostate cancer drug, Xtandi, compared to countries like Sweden, Japan and Canada.
MDVN: 58.89 (-0.08), VRX: 21.64 (unch)

Technical Data Influencing the Market - Analyst Notes on CUBA Beverage, Arch Therapeutics, Wolseley and Astellas Pharma
ACCESSWIRE - Wed Mar 09, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CUBA Beverage Co. (OTC: CUBV), Arch Therapeutics Inc. (OTC: ARTH), Wolseley PLC (OTC: WOSYY) and Astellas Pharma Inc. (OTC: ALPMY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

3 Reasons Medivation, Inc. Stock Could Rise
Cory Renauer, The Motley Fool - Motley Fool - Fri Mar 04, 2:39PM CST
Along with the rest of the healthcare industry,  Medivation   stock has had a rough year, even despite a 10% pop following recently-announced strong fourth-quarter earnings. The boost was especially welcome after the beating Medivation has received...
MDVN: 58.89 (-0.08), JNJ: 116.46 (+0.28)

Amgen Kyprolis' Label Expanded, Repatha Approved in Japan
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 3:30PM CST
The label for Amgen's (AMGN) Kyprolis has been expanded in the U.S. and accelerated approval has been converted to full approval; Repatha gains approval in Japan.
AMGN: 149.81 (+0.39), ANIK: 50.27 (+0.10), CELG: 99.23 (+2.37)

Where We Are Headed - Featured Research on Airbus Group, Astellas Pharma, Brambles and Detour Gold
ACCESSWIRE - Fri Jan 22, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Airbus Group SE (OTC: EADSY), Astellas Pharma Inc. (OTC: ALPMY), Brambles Ltd. (OTC: BXBLY) and Detour Gold Corp. (OTC: DRGDF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Ironwood Highlights Strategic Objectives, Provides Outlook
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 3:25PM CST
Ironwood Pharmaceuticals (IRWD) provided a comprehensive overview of its initiatives by highlighting three- and five-year operational and financial goals.
AGN: 228.55 (-3.00), IRWD: 12.64 (-0.04), AZN: 28.70 (+0.06)

Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:50PM CST
Vical's (VICL) antifungal candidate, VL-2397, was granted Orphan Drug designation for the treatment of patients with invasive aspergillosis.
VICL: 4.36 (+0.03), HZNP: 16.78 (+0.04), LGND: 113.83 (-0.16)

Ocata Therapeutics Almost Doubled in November -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Fri Dec 04, 3:03PM CST
What: Shares of eye-disease-focused  Ocata Therapeutics posted a huge 88% gain during the month of November after the company accepted a buyout offer for a healthy premium, according to data from S&P Capital IQ . So what:  Early in the...
OCAT: 8.47 (+0.01)

Ironwood/Astellas Report Positive Phase III Data on Linzess
Zacks Equity Research - Zacks Investment Research - Tue Dec 01, 3:55PM CST
Ironwood Pharmaceuticals (IRWD) and Astellas reported positive top-line phase III data on Linzess; Astellas will file for its approval in Japan in 2016.
AGN: 228.55 (-3.00), IRWD: 12.64 (-0.04), ACHN: 8.40 (-0.02)

Mallinckrodt (MNK) Sells Contrast Media & Delivery Systems
Zacks Equity Research - Zacks Investment Research - Mon Nov 30, 3:55PM CST
Mallinckrodt plc (MNK) announced that it has completed the previously announced divestiture of its global contrast media and delivery systems (CMDS) business to Guerbet for approximately $270 million.
MNK: 56.68 (+0.15), MYL: 45.00 (+0.12), CORT: 5.30 (-0.11)

Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod
Zacks Equity Research - Zacks Investment Research - Thu Nov 26, 12:20PM CST
Roche (RHHBY) received good news when the European Commission (EC) approved its skin cancer drug Cotellic (cobimetinib) for use in combination with Zelboraf (vemurafenib).
LLY: 73.07 (+0.50), EXEL: 7.74 (+0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Japan's RWE Market Transformation: TXP's Insightful Whitepaper

Updated Category News Views 25

Unraveling the Real-World Evidence Landscape in Japan The folks at TXP Medical just dropped a bombshell of a whitepaper that'll have Medical Affairs departments buzzing. Imagine waking up to a market that's exploding by over 500% in just a decade—yeah, I'm talking about the EMR-derived data market in Japan. These guys are saying it's gonna shoot from ¥3.9 billion in...

Continue Reading
Xi Jinping's Vision for China's Financial Evolution

Updated Category News Views 174

Xi's Blueprint for Financial Strength Xi Jinping isn't just whistling Dixie when it comes to reshaping China's financial landscape. His vision is about more than pushing paper; it's about embedding honesty, prudence, and traditional values into the very DNA of China's financial sector. When he talks about enhancing both hard and soft power, he’s thinking wider than...

Continue Reading
Curaleaf Eyes Aurora Amid Alternative from Organigram

Updated Category News Views 65

Curaleaf's Determined Pursuit of Aurora Another day, another chess move in the cannabis world. Curaleaf is standing tall amid talk of a buyout, putting a foot forward to highlight its determination in the battle for Aurora. They've put forth an alternative to the proposal poised by Organigram, raising stakes and eyebrows alike. Aurora Cannabis is in the middle of a dance...

Continue Reading
PRIMA Invests £10M to Propel CC Forum's Global Reach

Updated Category News Views 123

Strategic Commitment for Global Impact You've got to hand it to these folks—they're on a mission to roll up their sleeves and tackle climate change head-on. Max Studennikoff, the brains behind CC Forum, just inked a Letter of Intent with Alexander Zhardanovsky, founder of PRIMA, punctuated by an eye-popping £10 million pledge. It's all about boosting the Forum’s...

Continue Reading
Pyramid Pharma Takes On 13th Blood Cancer Therapy Product

Updated Category News Views 64

Pyramid Pharma: Breaking New Ground in Blood Cancer Treatments There's a new player making waves in the battle against rare blood cancers: Pyramid Pharma Services. This U.S.-based contract development and manufacturing organization is stepping up its game by finessing a cartridge-based product designed to treat those rare and tricky blood maladies. The canvas? A...

Continue Reading
Class Action Targets Coastal Financial Over Missteps

Updated Category News Views 32

New Crosshairs on Coastal Financial Corporation Man, it's another day and yet another fiasco in the corporate world. Late-breaking news from the trenches alerts us that Coastal Financial Corporation is in the legal spotlight. Yeah, you heard me right. We're talking about NASDAQ:CCB, the darlings turned defendants courtesy of recent allegations that could rock their stock....

Continue Reading
Atlas-SSI Expands Grip in Water Control Space

Updated Category News Views 86

Atlas-SSI Makes Waves with Linita Acquisition Here's the kind of news that makes an old market hound sit up and take notice. Atlas-SSI, the big cheese in North America for water management solutions, has gone and snagged Linita Design & Manufacturing. Why's this worth talking about? Linita isn't just any player—they've been crafting custom-engineered hydro-mechanical...

Continue Reading
Cloud Software Group Amends $2B Cash Tender Offer

Updated Category News Views 22

Cloud Software Group is stirring the pot with an amendment that'll have bondholders looking twice at their portfolios. On November 3, 2026, the company announced a tweak to its cash tender offer, bumping up the payment for its 9.00% Senior Secured Second Lien Notes due 2029. The payout now jumps from $1,017.50 to $1,022.50 for each $1,000 of principal. If you're holding...

Continue Reading
Differentia Bio's AI: Transforming Drug Development Dynamics

Updated Category News Views 51

The Future of Drug Development: AI's New Role When it comes to pharmaceutical R&D, Some outfits are playing pin the tail on the donkey, but Differentia Bio over here is sharpening the pin with some futuristic gadgetry. Yep, they're jazzing up the game with AI-powered digital twins, building lifelike disease environments that predict therapeutic outcomes with precision...

Continue Reading
Multiconsult's Q3 2026 Results: A Gradual Rebound

Updated Category News Views 30

Peering into the Q3 Crystal Ball When a company drops its quarterly results, it's like unveiling a new episode in an ongoing drama, and the Multiconsult ASA (Oslo: MULTI) saga is no exception. In their third quarter of 2026, the performance started to show signs of life following a somewhat sluggish run. While the numbers aren't sky-high, they're a solid indication that...

Continue Reading

Top 5 Most Recently Viewed Articles

Mobilizing for Equality: Texas AAPI Community Stands United

Updated Category News Views 275

Mobilizing for Equality: Texas AAPI Community Stands United Communities across Texas are coming together in a powerful display of solidarity against discriminatory Senate Bill 17 (SB 17) and House Bill 17 (HB 17). Both pieces of legislation propose to ban or severely restrict real estate ownership for certain foreign nationals, all while cloaked in the guise of protecting...

Continue Reading
Duke Energy Foundation's Commitment to Community Resilience Grows

Updated Category News Views 252

Duke Energy Foundation's Commitment to Community Resilience Duke Energy Foundation, along with Duke Energy, has made a significant impact by investing over $33 million in nonprofit organizations. This funding supports efforts aimed at enhancing community resilience, emergency preparedness, and disaster relief activities. The partnership extends across multiple states,...

Continue Reading
eCential Robotics Announces New Leaders to Boost Growth in US

Updated Category News Views 111

eCential Robotics Welcomes New Leadership to Accelerate Growth in the U.S. eCential Robotics, an innovator in surgical robotics, is thrilled to announce the recent appointments of Lisa Jacobs as President for North America and Matthieu Ville as Vice President of Marketing. These strategic hires are designed to bolster the company's growth and innovation efforts in the...

Continue Reading
Michelin's Latest Share Buyback Update Everyone Should Know

Updated Category News Views 220

Understanding Michelin's Share Buyback Program Michelin, a leader in tire manufacturing and innovation, is continuously taking steps to enhance its shareholder value. Investors often look for tangible actions reflecting a company's commitment to their financial growth. One of the most significant methods companies utilize to support their stock price and return capital to...

Continue Reading
InterDigital Boosts Third Quarter Forecast Following License Deal

Updated Category News Views 198

InterDigital's Promising New License Agreement and Q3 Outlook Smartphone Licensing Agreement Enhances Revenue Predictions Recently, InterDigital, Inc. (Nasdaq: IDCC), a prominent player in the mobile technology field, announced an exciting update that significantly alters its revenue expectations for the third quarter. The company has secured a major licensing agreement...

Continue Reading